Trial Profile
A phase III multicenter randomized clinical trial comparing gemcitabine alone or in combination with capecitabine for the treatment of patients with advanced pancreatic cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Feb 2016
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Capecitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 29 Nov 2012 United Kingdom Clinical Research Network reports accrual to date as 104%.
- 29 Nov 2012 New source identified and integrated (United Kingdom Clinical Research Network: 701).
- 26 Nov 2009 Actual end date (18 Jan 2005) added as reported by ISRCTN: Current Controlled Trials.